Bliss GVS Pharma Ltd

Bliss GVS Pharma Annual General Meeting

Bliss GVS Pharma concluded its 41st AGM on July 15, 2026. Shareholders approved a 100% final dividend of Re. 1.00 per share for FY 2025-26.

Bliss GVS Pharma Other Announcement

Bliss GVS Pharma updated contact details for KMPs authorized to determine and report material events. This administrative update ensures compliance with SEBI LODR Regulation 30(5).

Bliss GVS Pharma Employee Stock Options

Bliss GVS Pharma allotted ESOP shares, increasing paid-up capital. No monetary value disclosed; share count rose from 106.06M to 106.24M.

Bliss GVS Pharma Employee Stock Options

Bliss GVS Pharma allotted 1,87,750 shares under its ESOP plan. The share capital increased to Rs. 10,62,43,972 after this allotment.

Value

₹0.19 Cr

Bliss GVS Pharma Management Change

Bliss GVS Pharma appointed Rahul Adakmol as CEO, effective July 15, 2026. Narsimha Shibroor Kamath stepped down as CEO but remains Managing Director.

Bliss GVS Pharma Employee Stock Options

Bliss GVS Pharma allotted 2,67,250 equity shares under its ESOP 2019 to employees. The move increases paid-up capital and aligns employee interests with shareholders.

Bliss GVS Pharma Open Offer: ₹829 Cr

Anupam Rasayan announced a ₹829.03 Crore open offer for Bliss GVS Pharma. The acquirer seeks a 26% stake following a controlling share purchase agreement.

Value

₹829.0 Cr

Bliss GVS Pharma Business Update

Bliss GVS Pharma received a WHO-GMP Inspection Closure Report for its Palghar manufacturing facility. This certification confirms compliance with international quality standards for pharmaceutical manufacturing.

Bliss GVS Pharma Promoter Selling

Promoter Gagan Harsh Sharma sold 2,17,123 shares of Bliss GVS Pharma Limited via the open market. This transaction reduced his individual holding to nil.

Bliss GVS Pharma Open Offer: ₹805.1 Cr

Anupam Rasayan India Limited launched an ₹805.12 Crore open offer to acquire a 26% stake in Bliss GVS Pharma Limited. The offer price is set at ₹299 per share.

Value

₹805.1 Cr

Bliss GVS Pharma Open Offer: ₹829 Cr

Anupam Rasayan India Limited launched an ₹829.03 Crore open offer for Bliss GVS Pharma. The offer follows a 43.30% stake acquisition, aiming for a majority 69.51% holding.

Value

₹829.0 Cr

Execution

10 working days post-closure

Bliss GVS Pharma Other Announcement

Bliss GVS Pharma submitted its Annual Secretarial Compliance Report for FY2026. The report details governance adherence and provides updates on previous regulatory non-compliance matters.

Bliss GVS Pharma Management Change

Mr. Santosh Parab completed his final term as Independent Director on May 25, 2026. This planned leadership change follows statutory term limits for independent directors.

Bliss GVS Pharma Acquisition Worth ₹1,370 Cr

Anupam Rasayan India Limited is acquiring a 43.30% stake in Bliss GVS Pharma for ₹1,369.51 Crore. The deal triggers a mandatory 26% open offer.

Value

₹1,370 Cr

Bliss GVS Pharma Open Offer: ₹829 Cr

Anupam Rasayan launched a ₹829.03 Crore open offer to acquire a 26% stake in Bliss GVS Pharma. This follows a majority acquisition trigger via agreement.

Value

₹829.0 Cr

Execution

10 working days (Tendering Period)

Bliss GVS Pharma Promoter Selling

Promoter Punita Sharma sold 24,962 shares of Bliss GVS Pharma via the open market. This transaction reduces the seller's individual stake to zero.

Bliss GVS Pharma Q4 FY26 Results: Net Profit ₹37 Cr, Up 121.6% YoY

Bliss GVS Pharma Ltd reported revenue from operations of ₹257 Cr (+29.8% YoY) and net profit of ₹37 Cr (+121.6% YoY) for Q4 FY26.

Key figure

Net profit ₹37 Cr · +121.6% YoY

Bliss GVS Pharma Financial Results

Bliss GVS Pharma reported audited standalone and consolidated financial results for the year ended March 31, 2026. The Board also recommended a 100% final dividend.

Bliss GVS Pharma Employee Stock Options

Bliss GVS Pharma granted 1,80,000 stock options at Rs. 43 per share. The options vest over four years, aligning employee interests with long-term shareholder value.

Value

₹0.77 Cr

Execution

Vesting over 4 years; 6 months exercise period

Bliss GVS Pharma Annual General Meeting

Bliss GVS Pharma announced successful postal ballot results for appointing two independent directors. Shareholders approved both special resolutions with overwhelming majorities via remote electronic voting.

Bliss GVS Pharma Board Meeting Date

Bliss GVS Pharma Limited has scheduled a board meeting for May 12, 2026, to consider audited financial results for the year ended March 2026 and recommend a final dividend. The trading window for designated persons is closed from April 1, 2026, until May 14, 2026.

Bliss GVS Pharma Board Meeting Date

Bliss GVS Pharma Ltd has scheduled a board meeting on May 12, 2026, to approve audited standalone and consolidated financial results for FY2026. The board will also consider recommending a final dividend. The trading window for designated persons remains closed until 48 hours after the results announcement.

Bliss GVS Pharma Annual General Meeting

Bliss GVS Pharma Limited has issued a Postal Ballot notice seeking shareholder approval for the appointment of Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Independent Directors. Both appointments are for a five-year term effective from April 03, 2026. The e-voting period ends on May 09, 2026.

Execution

5 years

Bliss GVS Pharma Annual General Meeting

Bliss GVS Pharma Limited has issued a Postal Ballot Notice to seek shareholder approval for the appointment of Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Independent Directors for five-year terms. The e-voting period runs from April 10, 2026, to May 09, 2026, with results to be announced by May 12, 2026.

Bliss GVS Pharma Credit Rating

Bliss GVS Pharma Limited has been assigned a credit rating of [ICRA]A- (Stable) and [ICRA]A2+ by ICRA Limited for its bank facilities worth ₹100.00 Crore. This rating reflects the company's creditworthiness and stable financial outlook for its fund-based and non-fund-based instruments.

Value

₹100.0 Cr

Bliss GVS Pharma Management Change

Bliss GVS Pharma Limited has appointed Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Additional Independent Directors for five-year terms effective April 03, 2026. Both appointees are seasoned finance professionals and Chartered Accountants. The appointments are subject to shareholder approval via postal ballot.

Execution

5 years